Breathing Easier? The True Efficacy of Roflumilast in COPD Compared to Placebo
Submission: 05 February 2025 | Acceptance: 29 March 2025 | Publication: 28 April 2025
1Dr. Asma Qibtia, 2Dr. Ghulam Abbas Tahir, 3Dr. Muhammad Owais Fazal, 4Dr. Uneeba Syed, 5Dr. Zainab Asim, 6Dr. Aqsa Sadaf, 7Dr. Syed Kamal Husnain Shah
1Post-graduate resident, Internal Medicine, Allied Hospital I, Faisalabad.
2Assistant Professor (Medicine), Allied Hospital I, Faisalabad.
3Associate Professor (Medicine), Allied Hospital I, Faisalabad.
4Assistant professor of endocrinology, Endocrine department, Allama Iqbal medical college / Jinnah hospital lahore
5Post-Graduate Resident, Allied Hospital I, Faisalabad.
6Postgraduate resident, Internal Medicine, Allied Hospital I, Faisalabad.
7Senior Registrar (Medicine), Fellow Rheumatology, Madinah Teaching Hospital, Faisalabad.
Abstract
Aim: This study aimed to compare the effectiveness of roflumilast with placebo in patients with moderateto-severe chronic obstructive pulmonary disease (COPD).
Objective: The primary purpose was to evaluate lung function improvement, exacerbation frequency, and hospitalization rates from baseline (day 0) in patients receiving roflumilast versus placebo. Secondary outcomes included assessing the quality of life and the safety profile of roflumilast treatment.
Study Design: Randomized controlled trial
Setting: Outpatient department of Allied Hospital I, Faisalabad.
Duration: 6 Months
Materials and Methodology: 550 participants meeting the inclusion criteria, including age, GOLD stage 2–3 COPD, and the absence of significant comorbid respiratory diseases. Participants were randomized to receive either roflumilast or placebo for 12 months. Lung function was assessed using spirometry, while exacerbations and hospitalizations were meticulously recorded through patient diaries and medical records. Quality-adjusted life years (QALYs) were evaluated using patient-centered outcome questionnaires. Adverse events were graded for severity and systematically documented.
Results: Roflumilast significantly improved lung function, demonstrating a 120 mL increase in FEV1 compared to placebo (P < 0.001). The roflumilast group experienced 28% fewer exacerbations than the placebo group (rate ratio: 0.72, P < 0.001) and a lower hospitalization rate. However, adverse events were more frequent in the roflumilast group, primarily gastrointestinal symptoms and weight loss, leading to a higher discontinuation rate (10% vs. 5% for placebo).
Conclusion: Roflumilast is an effective treatment for improving lung function and reducing exacerbation frequency and hospital admissions in patients with moderate-to-severe COPD. Although adverse effects were generally manageable, physicians should consider patient tolerability and individual risk profiles when prescribing. These findings support roflumilast as a valuable therapeutic option in COPD management, potentially enhancing clinical outcomes and quality of life.
Keywords: COPD, Roflumilast, Lung Function, Quality of Life, Exacerbations.